Tumour angiogenesis: An elusive target in castration-resistant prostate cancer

The Lancet Oncology

Volumn 14, Issue 8, 2013, Pages 681-682

  Galsky, Matthew D ^a   Oh, William K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CABOZANTINIB; DOCETAXEL; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTIBODY RESPONSE; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG TREATMENT FAILURE; HUMAN; LETTER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84879787142     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70239-0     Document Type: Letter

References (9)

1. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Zetter BR The scientific contributions of M. Judah Folkman to cancer research. Nat Rev Cancer 2008, 8:647-654.
3. Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013, published online June 4. http://dx.doi.org/10.1016/S1470-2045(13)70184-0.
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
6. Galsky MD, Vogelzang NJ Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 2010, 21:2135-2144.
7. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012, 30:1534-1540.
8. Fazzari M, Heller G, Scher HI The phase II/III transition. Toward the proof of efficacy in cancer clinical trials. Control Clin Trials 2000, 21:360-368.
9. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013, 31:412-419.